secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001104659-25-040386
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics amends Crescent merger; exchange ratio ~15.42 GLYC shares per Crescent share
--------------------------------------------------------------------------------

- Amendment clarifies Crescent RSUs will be assumed using the same exchange ratio as other Crescent securities.
- Each Crescent share to receive approximately 15.4192 shares of GlycoMimetics common stock.
- Post-merger, GlycoMimetics holders expected to own ~2.6%; Crescent holders ~97.4% (fully diluted).
- GlycoMimetics net cash at closing assumed at $1.8 million for ownership calculation.
- Certificate of Designation for Series A Non-Voting Preferred Stock updated to clarify voting mechanics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000110465925040386/0001104659-25-040386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000110465925040386/tm2513409d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-040386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer